LeuTech Studies In Neutropenic Patients Suggested By FDA Committee
Palatin and co-development partner Mallinckrodt should conduct studies with LeuTech to verify efficacy in neutropenic patients and to ensure that the radiolabeled monoclonal antibody imaging agent does not damage white blood cells, FDA's Medical Imaging Drugs Advisory Committee suggested during a July 10 meeting.
You may also be interested in...
Palatin Technologies is conducting a cost-effectiveness analysis to support use of LeuTech to aid in the diagnosis of equivocal appendicitis.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011